Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael R Harrison

Showing results (181-190 of 183) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 183 results.
The Lancet. Oncology|August 21, 2019
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trialRobert J Motzer, Brian I Rini, David F McDermott, et al.
The Lancet. Oncology|March 5, 2019
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort studyNieves Martínez Chanzá, Wanling Xie, Mehmet Asim Bilen, et al.
Journal of the National Cancer Institute|August 11, 2023
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary TumorsTalal El Zarif, Amin H Nassar, Gregory R Pond, et al.
Pageof 19

Showing results (181-190 of 183) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 183 results.
The Lancet. Oncology|August 21, 2019
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trialRobert J Motzer, Brian I Rini, David F McDermott, et al.
The Lancet. Oncology|March 5, 2019
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort studyNieves Martínez Chanzá, Wanling Xie, Mehmet Asim Bilen, et al.
Journal of the National Cancer Institute|August 11, 2023
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary TumorsTalal El Zarif, Amin H Nassar, Gregory R Pond, et al.
Pageof 19